Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline Sells 289,774 Shares

Key Points

• CEO Matthew Gline sold 289,774 shares on April 16 at an average price of $29.16, generating about $8.45 million and reducing his ownership by 1.7% to 16,736,116 shares (valued at roughly $488.0 million).
• ROIV shares fell ~2.5% to $29.08 on Monday with 4.73 million shares traded (vs. average volume 6.07 million); the stock has a 12‑month range of $10.01–$30.33, a market cap of about $20.8 billion, and a negative P/E of -24.85.
• Analysts and institutions: the consensus rating is a "Moderate Buy" with a $30.55 target (10 Buys, 1 Hold, 1 Sell), and institutional investors own about 64.76% of the shares, with firms like Goldman Sachs increasing their stakes.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Matthew Gline sold 289,774 shares of the firm's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the completion of the sale, the chief executive officer owned 16,736,116 shares in the company, valued at $488,025,142.56. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Roivant Sciences Trading Down 2.5%

Shares of ROIV stock traded down $0.75 on Monday, reaching $29.08. 4,732,257 shares of the stock were exchanged, compared to its average volume of 6,073,326. Roivant Sciences Ltd. has a twelve month low of $10.01 and a twelve month high of $30.33. The company has a market capitalization of $20.81 billion, a price-to-earnings ratio of -24.85 and a beta of 1.20. The business's 50 day moving average price is $28.07 and its 200 day moving average price is $23.24.

Wall Street Analyst Weigh In

ROIV has been the topic of several recent research reports. HC Wainwright lifted their price objective on shares of Roivant Sciences from $33.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Guggenheim raised their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Citigroup lifted their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a report on Tuesday, February 10th. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Finally, Weiss Ratings cut shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, February 9th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $30.55.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in shares of Roivant Sciences by 15.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock worth $24,553,000 after purchasing an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Roivant Sciences by 1.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock worth $24,678,000 after buying an additional 34,341 shares in the last quarter. American Century Companies Inc. increased its position in Roivant Sciences by 1.9% during the second quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock worth $1,010,000 after buying an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. increased its position in Roivant Sciences by 149.9% during the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock worth $129,000 after buying an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp increased its position in Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company's stock worth $144,000 after buying an additional 1,181 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.